Showing results (41-50 of 108) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|July 7, 2019
Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapyChee Khoon Lee, Rebecca Asher, Michael Friedlander, et al.
Gynecologic Oncology|October 5, 2014
Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trialChee Khoon Lee, Sarah Lord, Tami Grunewald, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 9, 2018
Does a homeopathic medicine reduce hot flushes induced by adjuvant endocrine therapy in localized breast cancer patients? A multicenter randomized placebo-controlled phase III trialPierre-Etienne Heudel, Isabelle Van Praagh-Doreau, Bernard Duvert, et al.
Breast (Edinburgh, Scotland)|November 14, 2020
First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA studyAnne-Claire Hardy-Bessard, Fabien Brocard, Florian Clatot, et al.
Anticancer Research|July 5, 2020
GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian CancerFrÉdÉric Selle, Pierre-Etienne Heudel, Anne-Claire Hardy-Bessard, et al.
BMJ Open|March 4, 2022
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1Frédérique Berger, Margaux Marce, Suzette Delaloge, et al.
Journal of Geriatric Oncology|September 28, 2013
Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECOAlexandre Sostelly, Emilie Henin, Laure Chauvenet, et al.
European Journal of Cancer (Oxford, England : 1990)|April 12, 2018
Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancerConstance Thibault, Jean-Christophe Eymard, Alison Birtle, et al.
The Oncologist|September 19, 2025
Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancerB J Rimel, Eric Pujade-Lauraine, Kathleen Moore, et al.
Gynecologic Oncology|July 30, 2020
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT)Félix Blanc-Durand, Claudia Lefeuvre-Plesse, Isabelle Ray-Coquard, et al.
Pageof 11